S
Susanna A McColley
Researcher at Northwestern University
Publications - 4
Citations - 131
Susanna A McColley is an academic researcher from Northwestern University. The author has contributed to research in topics: Ivacaftor & Lumacaftor. The author has an hindex of 2, co-authored 4 publications receiving 22 citations. Previous affiliations of Susanna A McColley include Children's Memorial Hospital.
Papers
More filters
Journal ArticleDOI
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Edith T. Zemanick,Jennifer L. Taylor-Cousar,Jane Davies,Ronald L. Gibson,Marcus A. Mall,Edward F. McKone,Paul McNally,Bonnie W. Ramsey,Jonathan H. Rayment,Steven M. Rowe,Elizabeth Tullis,Neil Ahluwalia,Chenghao Chu,Thang Ho,Samuel M. Moskowitz,Sabrina Noel,S. Tian,David Waltz,Tanya G. Weinstock,Fengjuan Xuan,Claire E. Wainwright,Susanna A McColley,Susanna A McColley +22 more
TL;DR: In this article, Elexacaftor/tezacaftors/ivacaftors (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥ 12 years of age with CF and at least one F508del-CFTR (cystic fibrosis trans...
Journal ArticleDOI
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
Jordana E. Hoppe,Mark A. Chilvers,Felix Ratjen,John McNamara,Caroline A. Owen,S. Tian,Rachel Zahigian,Alexandra G Cornell,Susanna A McColley,Susanna A McColley +9 more
TL;DR: The long-term safety of lumacaftor-ivacaftar in a rollover study of children who participated in a previous multicentre, phase 3, open-label study of cystic fibrosis homozygous for the F508del-CFTR mutation was assessed.
Journal ArticleDOI
Cystic fibrosis year in review 2019: Section 2 pulmonary disease and infections.
TL;DR: During the year 2019, research and case reports/series in the field of cystic fibrosis (CF) were in abundance and to adequately address the large body of CF research published, the CF year in review will be divided into three sections, focusing specifically on new research related to pulmonary disease and infections.